DISCLAIMER: This page is intended for members of the general public in Belgium only.
The information provided on this site is intended for general information and education for Belgium-based members of the public and is not intended to be a substitute for the advice provided by a physician or other qualified healthcare professional.
Information about the NuvaxovidTM XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601)
NuvaxovidTM XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) has been granted full approval by the European Commission for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
Important information
For more information about the NuvaxovidTM XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601), download the Package Leaflet.
Report an Adverse Event (AE)
If you are concerned about any potential side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the Package Leaflet.
Either you or your healthcare professional can report any suspected adverse reactions via the national reporting system of Belgium.
Dutch
Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten
Afdeling Vigilantie
Galileelaan 5/03
1210 BRUSSEL Postbus 97
1000 BRUSSEL Madou
Website: www.eenbijwerkingmelden.be
e-mail: adr@fagg.be
French
Agence fédérale des médicaments et des produits de santé
Division Vigilance
Avenue Galilée 5/03
1210 BRUSSEL Boîte Postale 97
1000 BRUXELLES Madou
Site internet: www.notifieruneffetindesirable.be
e-mail: adr@afmps.be
German
Föderalagentur für Arzneimittel und Gesundheitsprodukte
Abteilung Vigilanz
Avenue Galilée - Galileelaan 5/03
1210 BRÜSSEL Postfach 97
1000 BRÜSSEL Madou
Website: www.notifieruneffetindesirable.be
e-mail: adr@fagg-afmps.be
Contact Us
Tel: +32 02 888 23 82
09:00 - 17:00
Monday - Friday